Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer.

ABSTRACT:

Purpose

Accurately predicting treatment response in metastatic colorectal cancer (mCRC) is critical to avoid unnecessary toxicity and improve patient outcomes. Patient-derived organoids (PDO) are promising models, but larger prospective studies are needed to confirm their predictive value.

Experimental design

Patients with mCRC underwent a metastatic biopsy for PDO establishment, before starting new systemic treatment. Predictors of PDO establishment were identified. PDOs were incubated with a seven-drug panel, including the patient's treatment, to determine drug sensitivity as measured by CyQUANT cell viability [area under the nonfitted "curve" of the raw viability or growth rate inhibition values (AUC and GRAUC) and concentration that gives half-maximal viability or GR inh

SUBMITTER: Smabers LP 

PROVIDER: S-EPMC12666313 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature